Molnupiravir
Molnupiravir is an antiviral drug that is currently under investigation for its potential use in the treatment of COVID-19. It was developed by the pharmaceutical companies Merck and Ridgeback Biotherapeutics.
History[edit | edit source]
Molnupiravir was initially developed for the treatment of influenza. It was discovered by scientists at Emory University and is based on the compound N4-hydroxycytidine. The drug works by introducing errors into the RNA of the virus, which prevents the virus from replicating.
Clinical Trials[edit | edit source]
In 2020, Molnupiravir entered Phase II clinical trials for the treatment of COVID-19. Preliminary results from these trials have shown that the drug may reduce the duration of infectiousness for individuals with COVID-19.
Mechanism of Action[edit | edit source]
Molnupiravir works by introducing errors into the RNA of the virus, which prevents the virus from replicating. This is achieved through the drug's active metabolite, EIDD-2801, which is incorporated into the virus's RNA.
Potential Side Effects[edit | edit source]
As with any drug, Molnupiravir may have potential side effects. These can include nausea, diarrhea, and headache. However, these side effects are generally mild and temporary.
See Also[edit | edit source]
Molnupiravir Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD